Compare Novo Nordisk A/S (NVO) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Twilio Inc — how do they compare? Novo Nordisk A/S trades at $45.08 (market cap $198.57B), while Twilio Inc trades at $227.24 (market cap $34.89B). The key difference: Novo Nordisk A/S is far larger — about 5.7× Twilio Inc's market cap, and Novo Nordisk A/S pays a 4.03% dividend while Twilio Inc pays none. Which is the better fit depends on your goals.
| NVO | TWLO | |
|---|---|---|
Market Cap | $198.57B | $34.89B |
Sector | Health | Technology |
52-Week High | $63.98 | $255.95 |
52-Week Low | $35.29 | $100.09 |
Enterprise Value | $213.37B | $33.30B |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Twilio (TWLO) trades at $225.89, down 3.04% on the day, showing strong fundamental momentum with three consecutive quarterly earnings beats and accelerating revenue growth from $3.8B in 2022 to $5.1B in 2025. The company has achieved profitability with net income turning positive at $33.83M in 2025 after years of losses, while technical indicators show neutral signals with support at $222 and resistance at $230.
TWLO presents a compelling growth story with 76.9% analyst buy ratings and a $267.25 consensus price target representing 18% upside. Key risks include premium valuation metrics (P/E 31.2, EV/EBITDA 66.3) and potential execution challenges in the competitive communications software space, though AI-driven product expansion provides growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
